New Delhi: Leading drug firms Aurobindo Pharma, Sun Pharma and Jubilant are recalling different products in the US market for various reasons, as per the latest enforcement report by the US Food and Drug Administration (USFDA). While Aurobindo Pharma is recalling Cyanocobalamin Injection, which is used to treat and prevent lack of vitamin B12, Mumbai-based Sun Pharma is recalling a drug used to increase the production of natural tears in eyes. Similarly, Jubilant Cadista is recalling a drug which is used to treat different inflammatory conditions. Jubilant Cadista Pharmaceuticals is a fully-owned subsidiary of Cadista Holdings Inc, which is a part of the Noida-based Jubilant Life Sciences. Click for more articles on Drug recall The USFDA stated that Aurobindo Pharma USA Inc, a unit of Hyderabad-based drug major, is recalling 4,33,809 vials of Cyanocobalamin injection for being a "Subpotent Drug". The New Jersey-based firm initiated the recall on April 5. The US health regulator noted that US-based Sun Pharmaceutical Industries Inc is recalling 73,030 boxes of Cequa (cyclosporine ophthalmic solution) for being a "Subpotent Drug". Besides, there was low out-of-specification results obtained for assay and the presence of particulate matter in the affected lot, USFDA stated as reasons for the company to initiate the recall. The company, a subsidiary of Sun Pharma, initiated the recall on April 1, this year. The USFDA noted that Salisbury-based Jubilant Cadista Pharmaceuticals Inc is recalling 19,222 bottles of Methylprednisolone tablets for being "Subpotent". Click for more articles on USFDA As per the US health regulator, New Jersey-based Macleods Pharma USA Inc is also recalling 4,872 bottles of a drug used to treat or prevent osteoporosis, manufactured at Baddi (Himachal Pradesh) due to "Failed content uniformity specifications." The USFDA has classified the recalls as Class III, which is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences." The US generic drug market was estimated to be around USD 115.2 billion in 2019. It is the largest market for pharmaceutical products. Other Drug recall Drug recall: Pfizer recalls some batches of Blood Pressure drug due to this reason Drug recall: Insulin Glargine recalled due to this reason Moderna recalls thousands of C-19 vaccine doses Drug recall: Certain Products recalled due to Microbial Contamination Drug Recall: IDArubicin Hydrochloride Injection recalled due to this reason Drug recall: Orphenadrine Citrate 100 mg Extended Release Tablets recalled due to this reason Drug recall: Pfizer recalls some batches of Blood Pressure drug due... NPPA panel rejects Cadila Healthcare’s application to fix retail price of... SEC of DCGI asked Bharat Biotech to provide more data on Covaxin for children aged below 12 Govt working on policy to boost R&D in Pharma Sector USFDA gives tentative nod to Alembic Pharma for Ivabradine tablets NPPA to set up digital platform to track availability of essential… AIDCOC has represented to MPSC to revise the education qualification advertised for the post of Assistant Commissioner IPGA in association with DCO INDIA DRUGS CONTROL FORUM organized an International Webinar on DESIGNER DRUGS NPPA expert panel decides not to fix ceiling price of Clotrimazole… Latest Notifications regarding Pharmaceuticals
https://thehealthmaster.com/2022/04/25/aurobindo-sun-pharma-recall-products-due-to-these-reasons/